1-6 of 6
James F Holland, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Predictors Of Response To Rigosertib In Patients With a Myelodysplastic Syndrome (MDS) Or Acute Myeloid Leukemia (AML) Relapsing After Or Refractory To Hypomethylating Agents

Shyamala C. Navada, MD, Rosalie Odchimar-Reissig, RN, E. Premkumar Reddy, PhD, Erin P Demakos, RN, CCRN, James F Holland, MD, Francois Wilhelm, MD, PhD., Lewis R. Silverman, MD
Journal: Blood
Blood (2013) 122 (21): 1527.
https://doi.org/10.1182/blood.V122.21.1527.1527
Published: 2013
Journal Articles

Evaluation of Rigosertib in Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I/II Study

Shyamala C. Navada, MD, Rosalie Odchimar-Reissig, RN, E. Premkumar Reddy, PhD, James F Holland, MD, Francois Wilhelm, MD, PhD., Lewis R. Silverman, MD
Journal: Blood
Blood (2012) 120 (21): 3794.
https://doi.org/10.1182/blood.V120.21.3794.3794
Published: 2012
Journal Articles

Dose Escalation of Azacitidine in Patients Failing Standard or Investigational Combinations of the Agent in the Myelodysplastiic Syndrome or Evolved AML

Lewis R. Silverman, MD, Shyamala C. Navada, MD, Rosalie Odchimar-Reissig, RN, Maria Michalak, PA-C, Erin P Demakos, RN, CCRN, James F Holland, MD
Journal: Blood
Blood (2012) 120 (21): 4932.
https://doi.org/10.1182/blood.V120.21.4932.4932
Published: 2012
Journal Articles

Evaluation of ON01910.Na In Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I Study

Lewis R Silverman, MD, Shyamala C. Navada, MD, Rosalie Odchimar-Reissig, RN, Vesna Najfeld, PhD, Takao Ohnuma, MD, Francois Wilhelm, MD, PhD., E. Premkumar Reddy, Ph.D., James F. Holland, MD
Journal: Blood
Blood (2010) 116 (21): 2944.
https://doi.org/10.1182/blood.V116.21.2944.2944
Published: 2010
Journal Articles

Analysis of Survival, AML Transformation, and Transfusion Independence in Patients with High-Risk Myelodysplastic Syndromes (MDS) Receiving Azacitidine Determined Using a Prognostic Model.

Lewis R. Silverman, MD, David R. McKenzie, MS, Bercedis L. Peterson, PhD, Erin P. Demakos, RN, CCRC, James F. Holland, MD, Richard R. Larson, MD, The Cancer Leukemia Group B (CALGB).
Journal: Blood
Blood (2005) 106 (11): 2523.
https://doi.org/10.1182/blood.V106.11.2523.2523
Published: 2005
Journal Articles

Azacitidine Prolongs Survival and Time to AML Transformation in High-Risk Myelodysplastic Syndrome (MDS) Patients ≥ 65 Years of Age.

Lewis R. Silverman, MD, David R. McKenzie, MS, Bercedis L. Peterson, PhD, Erin P. Demakos, RN, CCRC, Neil T. Malone, MA, James F. Holland, MD, Richard A. Larson, MD, The Cancer Leukemia Group B (CALGB).
Journal: Blood
Blood (2005) 106 (11): 2524.
https://doi.org/10.1182/blood.V106.11.2524.2524
Published: 2005